Empowering precision oncology with AI-driven insights

Tempus is a healthcare technology company advancing the use of AI in precision oncology. By integrating comprehensive molecular and clinical data, we deliver actionable insights that help oncologists make more informed decisions throughout the patient journey.

Contact us

Access a comprehensive oncology diagnostic portfolio to inform patient care at every step of the journey

Tempus offers a robust portfolio of tests—from germline and somatic testing to MRD and treatment response monitoring—providing a complete patient view to support clinical decisions.

 

Ready to order a test?

 

Visit Tempus Hub for fast, reliable ordering →

EARLY STAGE
LATE STAGE

Hereditary Risk Assessment

CancerNext®:  40-gene panel for hereditary cancer

CancerNext-Expanded®: 77-gene panel for hereditary cancer

+RNAinsight®: Optional RNA add-on

MRD & Response Monitoring

xM: Tumor-naive MRD assay

xM (NeXT Personal® Dx)*: Tumor-informed MRD and IO monitoring assay

Treatment Selection

xT CDx: FDA-approved 648-gene solid tumor + normal DNA seq panel

Learn more →

xT: Tumor only or Heme 648-gene DNA seq panel

Learn more →

xR: Whole-transcriptome RNA seq panel

Learn more →

xF/xF+: 105/523 gene cDNA seq panels

Learn more →

xE: Whole-exome DNA seq panel

Learn more →

Tailored Testing Add-ons

Algorithmic Tests:

HRD, UGT1A1, DPYD, IPS, TO, PurIST®

Learn more →

Biomarker Tests:

MMR, CLDN18, PD-L1, HER2, FOLR1, MGMT, C-MET, 1p/19q

Learn more →

Leverage rigorously validated insights to guide confident clinical decision-making

Every Tempus solution is grounded in science and supported by real-world evidence. Our insights help translate molecular data into meaningful action for every patient.

 

2K+ publications in leading scientific journals

 

View all publications →

content-column 1
content-column 2
content-column 3
content-column 4
content-column 5
content-column 6
content-column 1 (2)
content-column 2 (1)
content-column 3 (1)
content-column 4 (2)
content-column 5 (1)
content-column 6 (1)

Dual tissue + liquid testing

9%
Of patients had unique actionable alterations found in liquid biopsy that were not detected in solid tumor alone.
29%
More patients were identified with unique clinically actionable fusions with RNA sequencing.

Solid tumor + normal match

28%
Reduction in somatic false-positive calls, improving accuracy compared to a tumor-only analysis.

Streamline care with solutions that are seamlessly integrated into your existing workflows

Tempus solutions are built to work within your EHR and practice, making it easy to access insights, order tests, and take action—when and where you need them.

EHR INTEGRATION

EHR INTEGRATION

Easy access to current treatment options and relevant insights through our integration and connectivity capabilities.

Learn more
TEMPUS HUB

TEMPUS HUB

Fast, reliable platform for ordering Tempus tests, accessing patient insights, and utilizing our AI-driven technologies seamlessly.

Learn more
TEMPUS ONE

TEMPUS ONE

Providing access to patient insight directly at your fingertips with our AI-enabled clinical assistant.

Learn more

Obtain affordable and accessible testing through financial assistance

Tempus offers a transparent financial assistance program for all U.S. patients, ensuring cost is not a barrier to accessing high-quality molecular testing.

All U.S.-based patients are eligible to apply for financial assistance regardless of insurance status. For international patients, we offer a self-pay option. For any questions, please email patients@tempus.com.

Authorization for Medical Records: Through access.tempus.com, applicants are directed to our Notice and Authorization for Medical Records authorization form. This optional form allows us to request outcomes and other medical records from your health care providers. Please see the form for more information.

01

Applications for financial assistance can be submitted online at access.tempus.com ↗

02

If approved, the maximum out of pocket cost for testing will be provided immediately.

03

Please contact billing@tempus.com if you are concerned about out-of-pocket costs and would like to discuss your options.

Grow your precision medicine programs and reach more patients

Tempus is more than a lab—we're a strategic partner. Whether you're scaling a precision medicine program or optimizing one already in place, we offer support to help you expand access, increase trial enrollment, and deliver breakthrough care to patients.

TEMPUS NEXT

TEMPUS NEXT

Empowering you to deliver the next step in a patient’s care journey with our AI-enabled care pathway intelligence platform.

Learn more
CLINICAL TRIAL MATCHING

CLINICAL TRIAL MATCHING

Just-in-time clinical trial options for patients based on clinical and molecular data, for enrollment at your institution, through our TIME Trial Program—in days instead of months.

Learn more
PATHOLOGY SUPPORT

PATHOLOGY SUPPORT

AI capabilities to help pathologists find actionable markers in specimens to identify potential patients for clinical trials or precision therapeutics.

Learn more
TEMPUS+

TEMPUS+

Participating institutions receive access to technical support, customized to meet the unique needs and goals of your cancer center.

Learn more

Trusted by thousands of oncologists

 

We partner with community practices and more than 50% of all academic medical centers in the United States.

6.5K+
Oncologists rely on Tempus
40M+
Records across Tempus
4.5K+
Connected healthcare institutions
40+
Operational countries

Trusted by thousands of oncologists

Loading

Colorado GynOnc

“[Tempus] is more of a one-stop shop. Rather than sending patients to two or three different locations in order to get the same information, we can get all of it through Tempus. It is so much more convenient to get everything done with one test, one company, one set of results – instead of mixing and matching.”
Jeffrey A James, DO
Loading

TriHealth

“I am not just looking at Tempus as our partner in treatment, I see Tempus as our partner in prevention.”
James F Maher, MD
Loading

University of Illinois Chicago

“The IPS score can be very helpful in these settings because it gives us an added layer of understanding of who might have better outcomes to immunotherapy.”
Frank Weinberg, MD
media-container

OhioHealth

“In the rapidly changing world of cancer care and precision medicine, Tempus is the established leader. They provide rapid, accurate results while also continuing to develop innovative strategies to improve patient outcomes. With a focus on both clearly defining actionable mutations and extending treatment options by matching specific patients to specific local and national studies, Tempus is directly changing the patients lives.”
Joseph K Hofmeister, MD
media-container-1

Cleveland Clinic

“Breast cancer care has involved use of biomarkers for years in order to determine appropriate therapy. Genomic information has now been added to the list of crucial biomarkers needed to know how to treat metastatic breast cancer patients with the approval of targeted therapy for BRCA and PIK3CA mutations. Having this information also gives a patient the best opportunity to consider one of numerous biomarker driven clinical trials. These options allow as personalized an approach to treatment as possible and I have no doubt that genomic data will continue to transform the way patients are treated as our field moves forward.”
Megan Kruse, MD
Browse our FAQs

Comprehensive insights. A smarter tomorrow.

Every patient, new test and data point drives the breakthroughs of tomorrow.